Increased CD80(+) B cells in active multiple sclerosis and reversal by interferon beta-1b therapy

Area of Science:

• Immunology
• Neuroimmunology
• Cellular Biology

Background:

• Costimulatory molecules like CD80 and CD86 are crucial for T cell activation via binding to CD28 on T cells.
• T cell receptor (TCR) signaling without costimulation leads to anergy, while coupled signaling induces proliferation and cytokine secretion.
• Multiple sclerosis (MS) involves activated immune cells, elevated Th1 cytokines, and immune-mediated damage to oligodendroglia in the central nervous system.

Purpose of the Study:

• To investigate the role and expression levels of costimulatory molecules CD80 and CD86 in the context of multiple sclerosis (MS).
• To determine if CD80(+) lymphocytes can serve as a biomarker for disease activity and therapeutic response in MS patients.

Main Methods:

• Utilized two-color flow cytometry to analyze the expression of CD80, CD86, CD71, HLA-DR, and CD25 on circulating immune cells.
• Compared immune cell populations in patients during MS exacerbations, stable MS, and healthy individuals.
• Assessed the impact of Interferon beta-1b (IFN-beta) therapy on these cell populations.

Main Results:

• Circulating CD80(+) lymphocytes, predominantly B cells, were significantly increased during MS exacerbations but normalized in stable MS.
• Numbers of CD71(+) and HLA-DR(+) lymphocytes and monocytes were elevated in active MS.
• IFN-beta therapy reduced CD80(+) B cells and increased CD86(+) monocytes, along with decreasing HLA-DR(+), CD71(+), and CD25(+) mononuclear cells.

Conclusions:

• Increased CD80(+) B cells during MS exacerbations suggest their involvement in disease pathogenesis.
• CD80(+) cell counts may serve as a valuable surrogate marker for monitoring IFN-beta therapy efficacy in MS.
• Reduction of CD80-mediated costimulation is a potential therapeutic mechanism of IFN-beta in MS treatment.